Metformin in Longevity Study (MILES).
Public ClinicalTrials.gov record NCT02432287. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Metformin, an FDA approved first-line drug for the treatment of type 2 diabetes, has known beneficial effects on glucose metabolism. Evidence from animal models and in vitro studies suggest that in addition to its effects on glucose metabolism, metformin may influence metabolic and cellular processes associated with the development of age-related conditions, such as inflammation, oxidative damage, diminished autophagy, cell senescence and apoptosis. As such, metformin is of particular interest in clinical translational research in aging since it may influence fundamental aging factors that underlie multiple age-related conditions. The investigators therefore propose a pilot study to examine the effect of metformin treatment on the biology of aging in humans. Namely, whether treatment with metformin will restore the gene expression profile of older adults with impaired glucose tolerance (IGT) to that of young healthy subjects.
Study identification
- NCT ID
- NCT02432287
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 16 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 60 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2014
- Primary completion
- Aug 31, 2015
- Completion
- Nov 30, 2017
- Last update posted
- May 20, 2021
2014 – 2017
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Einstein College of Medicine of Yeshiva University | The Bronx | New York | 10461 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Aging trials
Other public records listing Aging. Sorted by last update posted; newest first. Not a recommendation.
- NCT06879626: Effect of Snacks on Aging Active, not recruiting
- NCT06501820: Neural Control of Gait & Navigation in ADRD Recruiting
- NCT07731451: The Role of Brain Lactate Metabolism in Neuroprotection During Healthy Aging Not yet recruiting
- NCT07719088: Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life Not yet recruiting
- NCT07719049: Artificial Intelligence-Based Health Assessment From Face Photographs - Healthy Volunteer Study Recruiting
- NCT07461584: Memory Enhancement in Aging With Optimal Dosing Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02432287, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2021 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02432287 live on ClinicalTrials.gov.